30 closest matches · ranked by relevance
Biliary Tract Cancer · Cholangiocarcinoma · Gallbladder Cancer
Primary: Percentage of Participants With Confirmed Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by…
HER2-amplified Biliary Tract Cancers
Primary: Confirmed Objective Response Rate (ORR) by Independent Central Review (ICR) — 33; 0 Participants
Cancer
Primary: Number of Participants With Indicated Non-progressive Disease as Assessed by Investigator Per Response Evaluation Criteria In Solid Tumor Version 1.1 (RECIST 1.1) at…
Biliary Tract Cancer
Primary: Objective Response Rate (ORR) — 11.5 percentage of participant
Biliary Tract Cancer
Primary: Progression Free Survival (PFS) — 7.92; 8.35 Months
Biliary Tract Neoplasms · Cholangiocarcinoma · Bile Duct Cancer
Primary: Progression Free Survival (PFS) — 4.54 Months
Biliary Tract Carcinoma
Primary: Overall Survival (OS) — 12.7; 10.9 Months — p=0.0034
Biliary Tract Carcinoma
Primary: Overall Survival (OS) — 14.1; 9.9 Months
Cholangiocarcinoma · Stage III Gallbladder Cancer AJCC v7 · Stage IIIA Gallbladder Cancer AJCC v7
Primary: 16-Week Progression-free Survival (PFS) Rate — 32.0 percentage of patients
Adenocarcinoma
Primary: Progression-free Survival (PFS) — 91; 148 days
Advanced Bile Duct Carcinoma · Advanced Gallbladder Carcinoma · Refractory Bile Duct Carcinoma
Primary: Progression-free Survival (PFS) — 37.0 percentage of participants
Stage III Distal Bile Duct Cancer AJCC v8 · Stage III Gallbladder Cancer AJCC v8 · Stage III Intrahepatic Cholangiocarcinoma AJCC v8
Primary: Overall Survival (OS) — 14.0; 13.6 months — p=0.41
Advanced Biliary Tract Carcinoma
Primary: MTD of MEK162 - Phase I — 45 mg
Biliary Tract Cancer · Gallbladder Cancer
Primary: The Number of Participants With Response to GEMOX-Panitumumab (GEMOX-P) in Chemotherapy naïve KRAS/ BRAF Wild Type Stage IV Biliary Tract Cancer Using the Response…
Extrahepatic Bile Duct Cancer · Gallbladder Cancer
Primary: Progression-Free Survival — 51 percentage of participants
Biliary Tract Cancer
Primary: Proportion of Patients Alive and Without Radiological or Clinical Progression at 4 Months — 54.8 percentage of participants
Biliary Tract Neoplasms · Liver Cancer · Hepatocellular Carcinoma
Primary: 6 Month Progression Free Survival (PFS) — 2.8; NA Months
Biliary Cancer · Cholangiocarcinoma
Primary: Progression Free Survival Rate at Five Months — 69 percentage of participants
Extrahepatic Bile Duct Cancer · Gallbladder Cancer
Primary: Stratum-specific (R0 and R1) 2-year Overall Survival — 67; 60 percentage of participants
Biliary Tract Cancer
Primary: Percentage of Patients Alive at 1 Year (1-Year Survival Rate) — 39; 31 percentage of participants
Biliary Tract Neoplasms
Primary: The Percentage of Patients Alive and Without Progression at 6 Months Following the Initiation of Treatment — 59.4; 21.2 percentage of participants
Stage III Intrahepatic Cholangiocarcinoma AJCC v7 · Stage IIIA Gallbladder Cancer AJCC v7 · Stage IIIB Gallbladder Cancer AJCC v7
Primary: Median Progression Free Survival (PFS) — 11.4; 14.9 months — p=0.62
Gastrointestinal Cancer · Biliary Tract Cancer
Primary: Part 1: Establish the Maximum Tolerated Dose (MTD) — 100 mg
Biliary Tract Cancer · Biliary Tract Neoplasms
Primary: Overall Response Rate (ORR) After 4 Cycles of Treatment — 22 percent
Advanced Primary Liver Cancer · Advanced Biliary Tract Carcinoma
Primary: The Safety and Tolerability — 28; 34; 92; 3 participants
Adult Primary Hepatocellular Carcinoma · Advanced Adult Primary Liver Cancer · Localized Unresectable Adult Primary Liver Cancer
Primary: Response Rate — 0; 5 percentage of responding patients
Adult Primary Cholangiocellular Carcinoma · Advanced Adult Primary Liver Cancer · Cholangiocarcinoma of the Extrahepatic Bile Duct
Primary: Overall Survival — 4.7; 1.6; 3.94 months
Cancer of the Bile Duct
Primary: Overall Survival (OS) at 6 Months — 7.9 months
Biliary Tract Cancer · Gallbladder Cancer · Cancer Of The Extrahepatic Bile Duct
Primary: Progression Free Survival — 105; 114; 148 days
Cholangiocarcinoma
Primary: The Primary Objective of This Study is to Assess Progression Free Survival (PFS) With Proposed Therapy for Patients With Locally Advanced or Metastatic Gallbladder and…